Chronic myelogenous leukemia following kidney transplantation in a pediatric patient.
The incidence of cancer is increased follow- ing kidney transplantation. Chronic myelogenous leukemia (CML) has been previously reported in ten adult patients and only one pediatric patient post kidney transplantation. We report one male patient aged 18.8 years, on chronic dialysis from the age of 2 years, who was transplanted from a cadaver donor at the age of 8 years. He was treated with recombinant human growth hormone (rhGH) before transplantation and with azathioprine after kidney transplantation. Eight years after transplantation, CML was diagnosed and he was successfully treated with hydroxyurea and alpha-interferon. The follow-up is 28 months. The possible role of the combined action of rhGH and azathioprine in CML genesis is discussed.
Mignozzi
M
M
Division of Nephrology and Dialysis, Bambino Gesù Children's Hospital and Research Institute, Piazza S. Onofrio 4, 00165 Rome, Italy. rizzoni@opbg.net
Picca
S
S
D000293:Adolescent; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001379:Azathioprine / Q000009:adverse effects / Q000627:therapeutic use; D019382:Human Growth Hormone / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000009:adverse effects*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000139:chemically induced / Q000188:drug therapy / Q000209:etiology*; D008297:Male; D011994:Recombinant Proteins / Q000009:adverse effects / Q000627:therapeutic use
D000970:Antineoplastic Agents; D007166:Immunosuppressive Agents; D016898:Interferon-alpha; D011994:Recombinant Proteins; D019382:Human Growth Hormone; D001379:Azathioprine; D006918:Hydroxyurea